Notwithstanding positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. Such organizations are often building limitations to access, like high cost requirements and app